Gennaro Sardella
YOU?
Author Swipe
View article: Mitral Transcatheter edge-to-edge repair rivals surgery for survival despite less complete correction: a systematic review and metanalysis of randomized and propensity score matching studies
Mitral Transcatheter edge-to-edge repair rivals surgery for survival despite less complete correction: a systematic review and metanalysis of randomized and propensity score matching studies Open
Aims To compare outcomes of patients with severe mitral regurgitation (MR) after m-TEER and surgery. Methods and results PubMed, Scopus, and Google Scholar databases were searched for randomized controlled trials and propensity score match…
View article: Restoration of a Stuck Leaflet
Restoration of a Stuck Leaflet Open
Severe aortic regurgitation (AR) for a leaflet malfunction after transcatheter aortic valve implantation (TAVI) is a dreadful complication that can lead even to cardiogenic shock. New valve's design has reduced the rate of paravalvular reg…
View article: The Role of High-Sensitivity Troponin T Regarding Prognosis and Cardiovascular Outcome across Heart Failure Spectrum
The Role of High-Sensitivity Troponin T Regarding Prognosis and Cardiovascular Outcome across Heart Failure Spectrum Open
Background: Cardiac troponin release is related to the cardiomyocyte loss occurring in heart failure (HF). The prognostic role of high-sensitivity cardiac troponin T (hs-cTnT) in several settings of HF is under investigation. The aim of th…
View article: DOUBLE ST–ELEVATION, DOUBLE OCCLUSION?
DOUBLE ST–ELEVATION, DOUBLE OCCLUSION? Open
Case Presentation A 71–year–old woman was referred to our outpatient clinic for two episodes of chest pain during last two days. Her past medical history was remarkable for arterial hypertension, obesity, diabetes mellitus type 2 treated b…
View article: Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial
Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial Open
View article: Stroke Risk during TAVR: Is Prevention Better than Cure?
Stroke Risk during TAVR: Is Prevention Better than Cure? Open
Periprocedural stroke is an uncommon but feared complication in patients undergoing transcatheter aortic valve replacement (TAVR). Typically embolic, it occurs more frequent in the first days (within seven days) after the procedure and it …
View article: 1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program
1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program Open
This analysis aimed to evaluate the effect of 1- versus 3-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in older patients. Data from 3 prospective, single-arm studies (XIENCE Short DAPT Program), inc…
View article: Impact of the COVID-19 Pandemic on Global TAVR Activity
Impact of the COVID-19 Pandemic on Global TAVR Activity Open
View article: Invasive and Conservative Management of Old or Frail Patients Presenting with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials and Adjusted Observational Studies
Invasive and Conservative Management of Old or Frail Patients Presenting with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials and Adjusted Observational Studies Open
View article: Contents
Contents Open
View article: One-month dual antiplatelet therapy following stent implantation in patients with acute coronary syndromes and high bleeding risk
One-month dual antiplatelet therapy following stent implantation in patients with acute coronary syndromes and high bleeding risk Open
Background/introduction There is a paucity of data regarding the safety of a one-month dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) in patients at high bleeding risk (HBR) presenting with acute corona…
View article: Repeat coronary revascularization in high-risk patients treated with ticagrelor monotherapy after PCI: Insights from the randomized TWILIGHT trial
Repeat coronary revascularization in high-risk patients treated with ticagrelor monotherapy after PCI: Insights from the randomized TWILIGHT trial Open
Background Repeat revascularization after percutaneous coronary intervention (PCI) remains a major concern, even though its impact on mortality is limited. The effect of ticagrelor monotherapy vs. standard dual antiplatelet therapy (DAPT) …
View article: Coronary calcification in patients presenting with acute coronary syndromes: insights from the MATRIX trial
Coronary calcification in patients presenting with acute coronary syndromes: insights from the MATRIX trial Open
Aims The role of coronary calcification on clinical outcomes among different revascularization strategies in patients presenting with acute coronary syndromes (ACSs) has been rarely investigated. The aim of this investigation is to evaluat…
View article: Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial
Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial Open
View article: Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention Open
View article: 1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI
1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI Open
Between 1 and 12 months after PCI, 1-month compared with 3-month DAPT was associated with similar rates of all-cause death or MI and a reduced rate of BARC types 2 to 5 bleeding, irrespective of OAC treatment.
View article: Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions Open
View article: Impact of Complete Revascularization on Development of Heart Failure in Patients With Acute Coronary Syndrome and Multivessel Disease: A Subanalysis of the CORALYS Registry
Impact of Complete Revascularization on Development of Heart Failure in Patients With Acute Coronary Syndrome and Multivessel Disease: A Subanalysis of the CORALYS Registry Open
Background The impact of complete revascularization (CR) on the development of heart failure (HF) in patients with acute coronary syndrome and multivessel coronary artery disease undergoing percutaneous coronary intervention remains to be …
View article: Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA): Focus on Coronary Microvascular Dysfunction and Genetic Susceptibility
Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA): Focus on Coronary Microvascular Dysfunction and Genetic Susceptibility Open
Among the most common causes of death worldwide, ischemic heart disease (IHD) is recognized to rank first. Even if atherosclerotic disease of the epicardial arteries is known as the leading cause of IHD, the presence of myocardial infarcti…
View article: Coronary Lithotripsy as Elective or Bail-Out Strategy After Rotational Atherectomy in the Rota-Shock Registry
Coronary Lithotripsy as Elective or Bail-Out Strategy After Rotational Atherectomy in the Rota-Shock Registry Open
View article: LB-9 | Repeated Coronary Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial
LB-9 | Repeated Coronary Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial Open
Repeat revascularization after percutaneous coronary intervention (PCI) remains a major concern, even though its impact on mortality is limited. The effect of ticagrelor monotherapy vs. standard dual antiplatelet therapy (DAPT) on this out…
View article: Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial
Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial Open
Aim The aim of this study was to assess the effect of ticagrelor monotherapy among high-risk patients with anaemia undergoing percutaneous coronary intervention (PCI). Methods and results In the TWILIGHT (Ticagrelor with Aspirin or Alone i…
View article: 471 IMPACT OF COMPLETE REVASCULARIZATION ON DEVELOPMENT OF HEART FAILURE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND MULTIVESSEL DISEASE
471 IMPACT OF COMPLETE REVASCULARIZATION ON DEVELOPMENT OF HEART FAILURE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND MULTIVESSEL DISEASE Open
Background The impact of complete revascularization (CR) on survival and occurrence of heart failure (HF) after ACS is still unsettled. Goal of this study was to evaluate the impact of CR on HF hospitalization and adverse outcomes in patie…
View article: Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study Open
In high-risk patients with prior CABG, ticagrelor monotherapy reduced bleeding without compromising ischaemic outcomes compared with ticagrelor plus aspirin.
View article: Dataset related to article "One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients"
Dataset related to article "One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients" Open
This record contains raw data related to article "One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients" Abstract: Background It is unknown whether contemporary drug-elutin…
View article: Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index Open
View article: Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry
Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry Open
gov: NCT02362659.
View article: Impact of different antiplatelet therapy cessation modes on outcomes in patients treated with ticagrelor with or without aspirin after PCI: the twilight-antiplatelet cessation study
Impact of different antiplatelet therapy cessation modes on outcomes in patients treated with ticagrelor with or without aspirin after PCI: the twilight-antiplatelet cessation study Open
Background The Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention (TWILIGHT) trial showed that a regimen consisting of a 3-month dual antiplatelet therapy (DAPT) followed by ticagrelor monotherapy reduces th…
View article: TCT-549 Impact of COVID-19 Pandemic on TAVR Activity: A Worldwide Registry
TCT-549 Impact of COVID-19 Pandemic on TAVR Activity: A Worldwide Registry Open
View article: Coronary Stenting in High Bleeding Risk Patients With Small Coronary Arteries Followed by One-Month Dual Antiplatelet Therapy: Onyx ONE Clear
Coronary Stenting in High Bleeding Risk Patients With Small Coronary Arteries Followed by One-Month Dual Antiplatelet Therapy: Onyx ONE Clear Open
Among patients at HBR treated with a ZES and 1-month DAPT, those with SVD had favorable 12-month ischemic and bleeding outcomes, which were comparable with those of patients with larger caliber vessels.